Study of Atiprimod Treatment for Patients With Advanced Cancer
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to
evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360
mg/day, or the MTD, whichever is lower, in patients with advanced cancer.
Secondary Objectives:
The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and
to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to
compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the
intent of switching to capsules for the dose escalation if the capsules pose no safety
issues.